Compare Ascendis Pharma A/S (ASND) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Quantum Computing Inc — how do they compare? Ascendis Pharma A/S trades at $255.19 (market cap $16.67B), while Quantum Computing Inc trades at $8.92 (market cap $2.03B). The key difference: Ascendis Pharma A/S is far larger — about 8.2× Quantum Computing Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| ASND | QUBT | |
|---|---|---|
Market Cap | $16.67B | $2.03B |
Sector | Health | Technology |
52-Week High | $277.18 | $24.62 |
52-Week Low | $189.74 | $6.31 |
Enterprise Value | $17.04B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Quantum Computing Inc. (QUBT) trades at $9.07, up 1.57% with bearish technical signals despite recent revenue growth. The company reported Q2 2026 revenue of $5.6 million, a significant increase from prior periods, though profitability remains challenged with negative margins. Analyst consensus is bullish with a $18.50 price target, while institutional interest grows with recent purchases by Amundi and Bank of New York Mellon.
QUBT presents high-risk, high-reward potential with strong revenue growth from photonics sales but faces execution risks and negative profitability. The stock's 75% buy rating from analysts suggests upside potential, though investors must weigh the speculative nature against substantial cash reserves and expanding manufacturing capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
